The 2014 ESC/EACTS Guidelines on Myocardial Revascularization provide comprehensive recommendations for the management of patients with coronary artery disease (CAD). The guidelines emphasize the importance of a multidisciplinary approach, known as the 'Heart Team,' involving cardiologists, cardiac surgeons, and interventional cardiologists, to make informed decisions about revascularization strategies. The guidelines cover various aspects of myocardial revascularization, including risk stratification, diagnostic testing, and the selection of appropriate revascularization techniques such as percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG). The guidelines highlight the use of risk scores such as the EuroSCORE II and SYNTAX score to assess the risks and benefits of revascularization. They also emphasize the importance of patient information and informed consent, ensuring that patients understand the risks and benefits of different treatment options. The guidelines recommend that patients with stable CAD should undergo revascularization within 2 weeks if they have severe symptoms or high-risk anatomy, while other patients should undergo revascularization within 6 weeks. The guidelines also address the use of non-invasive and invasive diagnostic tests to assess the extent of CAD and determine the need for revascularization. They recommend that patients with intermediate pre-test probability of significant CAD should undergo ischaemia imaging, such as stress echocardiography or perfusion scintigraphy. The guidelines also emphasize the importance of antithrombotic therapy and the management of comorbid conditions such as diabetes and chronic kidney disease. The guidelines provide evidence-based recommendations for the use of PCI and CABG, including the use of drug-eluting stents and the selection of appropriate grafts for CABG. They also address the management of patients with acute coronary syndromes, including the use of primary percutaneous coronary intervention (PCI) and fibrinolysis. The guidelines emphasize the importance of a balanced approach to revascularization, considering the patient's individual circumstances and the potential risks and benefits of different treatment strategies. The guidelines are intended to assist healthcare professionals in making informed decisions about the best management strategies for individual patients with CAD.The 2014 ESC/EACTS Guidelines on Myocardial Revascularization provide comprehensive recommendations for the management of patients with coronary artery disease (CAD). The guidelines emphasize the importance of a multidisciplinary approach, known as the 'Heart Team,' involving cardiologists, cardiac surgeons, and interventional cardiologists, to make informed decisions about revascularization strategies. The guidelines cover various aspects of myocardial revascularization, including risk stratification, diagnostic testing, and the selection of appropriate revascularization techniques such as percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG). The guidelines highlight the use of risk scores such as the EuroSCORE II and SYNTAX score to assess the risks and benefits of revascularization. They also emphasize the importance of patient information and informed consent, ensuring that patients understand the risks and benefits of different treatment options. The guidelines recommend that patients with stable CAD should undergo revascularization within 2 weeks if they have severe symptoms or high-risk anatomy, while other patients should undergo revascularization within 6 weeks. The guidelines also address the use of non-invasive and invasive diagnostic tests to assess the extent of CAD and determine the need for revascularization. They recommend that patients with intermediate pre-test probability of significant CAD should undergo ischaemia imaging, such as stress echocardiography or perfusion scintigraphy. The guidelines also emphasize the importance of antithrombotic therapy and the management of comorbid conditions such as diabetes and chronic kidney disease. The guidelines provide evidence-based recommendations for the use of PCI and CABG, including the use of drug-eluting stents and the selection of appropriate grafts for CABG. They also address the management of patients with acute coronary syndromes, including the use of primary percutaneous coronary intervention (PCI) and fibrinolysis. The guidelines emphasize the importance of a balanced approach to revascularization, considering the patient's individual circumstances and the potential risks and benefits of different treatment strategies. The guidelines are intended to assist healthcare professionals in making informed decisions about the best management strategies for individual patients with CAD.